Frontlight ResearchEarly access
CompletedPhase 2
ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection
Key facts
- Who runs it
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Where
- China5 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 119 people enrolled
- Started
- 31 May 2021
- Ended
- 6 Mar 2024
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Aminolaevulinic acid (500-mg bottle)
- Aminolaevulinic acid (750-mg bottle)
- Placebo
- Record updated
- 3 June 2024
Who can take part
- Age
- 18 years to 45 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Premenopausal women, 18-45 years of age
- Satisfactory the colposcopy examination (cervical transformation zone types: Type 1 or 2) at screening, and CIN2 as verified by cervical biopsy and p16-positivity within the last 3 months
- Intense desire to retain the cervical structure or function
- High-risk (including probably/possibly carcinogenic) HPV-DNA (i.e. 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 or 82) positive within the last 3 months
- Meet the following conditions: pregnancy test negative; no pregnancy plan during the trial;no sexuality or reliable contraceptive measures taken since last menstruation to the onset of the study, agreeing to adopt reliable contraceptive measures during the study
- Signed written informed consent
Who cannot take part
- History of treatment with systemic antivirals (continued for ≥ 14 days) within the last 3 months
- Atypical glandular cells (AGS) or adenocarcinoma in situ (AIS) on cytology ,or malignant cells on cytology or histology, or other suspicion of either micro-invasive or invasive disease
- Severe pelvic inflammatory disease, severe cervicitis, or other severe gynaecological infection as per clinical examination
- Undiagnosed vaginal bleeding within the last 3 months
- With allergic disease at present; known or suspected porphyria; known allergy to ALA or analogues
- With serious cardiovascular, neurologic, psychiatric, endocrine, hematological disease; immunocompromised conditions or long-term glucocorticoid or immunosuppressants exposure; patients with malignant tumors within the last 5 years
- Hepatic or renal functions abnormal (alanine aminotransferase or aspartate transaminase > 3 upper limit of normal [ULN], or total bilirubin > 1.5 ULN, or serum creatinine or blood urea nitrogen > 1.5 ULN)
- Invasive carcinoma possibility or lesions extending to the vaginal wall
- Pregnancy or nursing
- Participation in any clinical studies within the last 30 days
- Poor compliance or inability to complete the trial
- Subjects that the investigators judged to be not suitable to participate the study besides above
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Efficacy and Safety of ALA-PDT in patients with cervical intraepithelial neoplasia grade 2 (CIN2) in p16-positivity and high-risk HPV infection.
The 3 groups in the trial
- ALA A GroupTreatment being tested
ALA 500mg Group
Treatment: Aminolaevulinic acid (500-mg bottle)
- ALA B GroupTreatment being tested
ALA 750mg Group
Treatment: Aminolaevulinic acid (750-mg bottle)
- PlaceboPlacebo, for comparison
Placebo Group
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-center, Randomized, Double-blind, Placebo-controlled Phase IIc Clinical Trial of ALA-PDT in Patients With Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in p16-positivity and High-risk HPV Infection
- Record updated
- 3 June 2024